BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
363.42
-7.45 (-2.01%)
Oct 27, 2026, 12:52 PM EDT - Market open
BeOne Medicines AG Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, BeOne Medicines AG stock has a consensus rating of "Strong Buy" and an average price target of $436.46. The average 1-year stock price forecast is 20.10% higher than the current stock price, while the lowest is $370 (+1.81%) and the highest is $528 (+45.29%).
Price Target: $436.46 (+20.10%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 19 | 19 | 20 | 20 | 20 | 19 |
| Buy | 8 | 8 | 8 | 7 | 7 | 7 |
| Hold | 1 | 1 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 28 | 28 | 28 | 28 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $466 | Buy | Maintains | $466 | +28.23% | Oct 20, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $459 | Buy | Maintains | $459 | +26.30% | Oct 17, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $405 → $425 | Buy | Reiterates | $405 → $425 | +16.94% | Oct 16, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $400 | Buy | Maintains | $400 | +10.07% | Oct 16, 2026 |
| Truist Financial | Truist Financial | Buy Maintains $418 → $420 | Buy | Maintains | $418 → $420 | +15.57% | Oct 9, 2026 |
Financial Forecast
Revenue This Year
6.76B
from 5.34B
Increased by 26.56%
Revenue Next Year
7.76B
from 6.76B
Increased by 14.78%
EPS This Year
0.63
from 0.19
Increased by 233.51%
EPS Next Year
0.90
from 0.63
Increased by 42.29%
EPS and Forward PE are based on non-GAAP adjusted numbers.